Harmony Biosciences Holdings, Inc. (HRMY)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A
Pipeline Grade

Financial Position (from SEC Filings)

$589.7M
Cash & Equivalents
$27.8M
Quarterly Burn Rate
$1,781M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
PITOLISANT HYDROCHLORIDE
WAKIX 		APPROVED —

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06014281 Examining the Effects of Regular Brief Internet-based Meditation Practice on Mental Health and Well Being OTHER Active Not Recruiting 300

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for HRMY.

SEC EDGAR Filings

All SEC filings for Harmony Biosciences Holdings, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.